Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-12-02
1998-03-17
Cook, Rebecca
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514396, 514926, 514927, A61K 31435
Patent
active
057287112
ABSTRACT:
An infection with Helicobacter may successfully be treated with a compound of the formula ##STR1## wherein R.sub.1 is hydrogen or methyl and R.sub.2 is hydrogen or L-alanine-L-alanyl, and the pharmaceutically acceptable acid additive salts thereof. These compounds are useful in the treatment of gastric and duodenal ulcers.
REFERENCES:
patent: 5116821 (1992-05-01), Randall et al.
patent: 5164402 (1992-11-01), Brighty
patent: 5196205 (1993-03-01), Borody
patent: 5447923 (1995-09-01), Catrenich et al.
patent: 5476669 (1995-12-01), Borody
patent: 5478818 (1995-12-01), Niimura et al.
patent: 5618564 (1997-04-01), Kimura et al.
B. Marshall, The Lancet, 1774-May 1983.
J.R. Warren, The Lancet, 1273 (1983).
Fedotin, Modern Medicine, 60, 61-70 (1992).
Czinn et al, Adv. Pediatr. Infect. Dis. 1990, 5, 221-37.
NIH Consensus Devt. Conf., 77-79, Feb. 7-9, 1994.
Canton et al., Rev. Esp. Enf. Digest, 78 (Suppl. I), 98(102), abstract #P-209 (1990);.
Peyre et al., Rev. Esp. Enf. Digest, 78 (Suppl. I), 107, abstract #P-232 (1990);.
Daskalopoulos et al., Rev. Esp. Enf. Digest, 78 (Suppl. I), 113, abstract #P-244 (1990);.
Molnar et. al., Irish J. Med. Science, 161 (Suppl. 10), 99, abstract #T44 (1992);.
Bayerdorffer et al., Deutsche Medizinische Wochenschrift 112, 1407-1411 (1987); abstract.
Hardy et al., J. Antimicrob. Chemother, 22, 631-636 (1988);.
Sachdeva et al., ICAAC, 107, abstract # 41 (1989);.
Labenz et al., Rev. Esp. Enf. Digest, 78 (Suppl. I) 104, abstract #P-224 (1990);.
Glupczynski et al. The Lancet: May 9, 1987, 1096 (1987);.
Mertens et al., Antimicrob. Agents Chemother, 33, 256-257 (1989);.
Forsmark et al., J. Infect. Dis., 162, 998 (1990);.
Vicenzi et al., Rev. Esp. Enf. Digest, 78 (Suppl. I), 114, abstract #P-248 (1990).
Westblom et al., J. Infect, Dis., 165, 974-975 (1992);.
Haas et al., Antimicrob. Agents Chemother, 34, 1637-1641 91990);.
Caekenberghe et al., Antimicrobial Agents and Chemotherapy, 31, 1429-1430 (1987);.
Nakao et al., Eur. J. Clin. Microbiol. Infect. Dis., 14, 391-399 (1995);.
Colin-Jones, Lancet, 1467 (1987);.
NIH Consensus Development Conference on Helicobacter pylori in Peptic Ulcer Disease, Feb. 7-9 (1994);.
Carley et al., J. Antimicrobial Chemotherapy, 24, 266-268 (1989);.
Glupczynski et al., Eur. J. Epidemiol., 4, 154-157 (1988);.
McNulty et al., Eur. J. Clin. Microbiol Infect. Dis., 7,566--569 (1988);.
Marshall, Gastroenterology Clinics of North America, 22, 183-198 (1993);.
Simor et al., Antimicrobial Agents and Chemotherapy, 33, 108-109 (1989).
Girard Arthur E.
Gootz Thomas D.
Cook Rebecca
Ginsburg Paul H.
Holtrust Gezina
Pfizer Inc.
Richardson Peter C.
LandOfFree
Treatment of H. pylori infections does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of H. pylori infections, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of H. pylori infections will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-957962